Bio2Device Group, Tuesday Morning, Oct. 30, 2012
Topic: “Integrating Reimbursement into Early Stage Diagnostic Development”
Speaker: Stanley Skrzypczak, M.S., M.B.A., Senior Director, Commercial Development, Genomic Health
Date and Time: Tuesday morning, Oct. 30, 2012, 8:30am
Location: Sunnyvale City Council Chambers, 456 West Olive Ave., Sunnyale, CA
No registration is required.
Early stage development programs in diagnostics, pharmaceuticals, and medical devices have historically directed efforts toward generating sufficient evidence for approval by regulatory bodies and generating physician adoption and demand. In molecular diagnostics, the evolving business model for evidence generation has been extended from evidence to support clinical validation and clinical utility to now supporting reimbursement and inclusion to guidelines. Incorporating reimbursement into the early stage planning process can enhance the probability for coverage but also the time to reimbursement. Factors involved and the significance of this planning approach will be explored in the lecture.
Stanley Skrzypczak, M.S., M.B.A., Senior Director, Commercial Development was previously Senior Director of Oncotype Marketing and Director of Managed Care Marketing, at Genomic Health. He has over 25 years of successful biotech and pharmaceutical sales and marketing experience, including product, managed care, clinical marketing and sales management. In his last position at Genentech, he was the Senior Product Manager for Xolair Marketing. Stan initially built a career in field sales and management for 7 years at Searle Pharmaceuticals, prior to joining Genentech where he worked for 18 years.